Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.62-5.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DARE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage dilution from equity sales | A supporting condition in Dare Bioscience Inc's published investment case. The stated target is No further large unregistered equity sales in next 4 quarters. | Under Pressure | Company announces new large equity offerings within next 4 quarters | New $6M registered direct offering announced Aug 2026 DARE priced a $6M registered direct offering in August 2026, violating the no-new-equity-sales target. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, meaning the long-term thesis depends on products and clinical programs that are still developing. The thesis is in a watch state: early revenue is appearing, but financial performance remains weak and management execution is described as volatile.
DARE is valued at a premium to peers, though the valuation model has low confidence and the premium appears tied to future opportunities rather than established earnings. The evidence does not give a clear account of what investors already expect, and no valuation fragility warning has fired.
Near term, DARE to PLAY Sildenafil Cream revenue rose from the first to the second quarter of 2026, while Flora Sync LF5 has begun its commercial launch with revenue timing less clear. The pipeline has advanced, including positive interim Phase 3 Ovaprene results, but the company remains loss-making and faces elevated risk around its next report. A guidance cut would be a meaningful negative; the sector backdrop has improved, but recent financial performance remains below its industry cohort.
Over the next one to three years, the thesis hinges on whether early product activity develops into meaningful, sustained revenue and whether Ovaprene and DARE-HPV reach their stated milestones. Near-term guidance, continued execution on launches, and the broader Healthcare backdrop are key swing factors; weakening jobs data could also weigh on the sector.
DARE has early commercial and pipeline progress, but its multi-year view remains uncertain because losses, execution risk, and a peer valuation premium leave little evidence of an established earnings base. The central test is whether launches and clinical milestones translate into durable financial progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS loss narrowing toward -$0.51 in FY27 |
| Losses are narrowing, with EPS improving from -$0.95 this year to -$0.51 next year. |
| Improving |
| EPS loss worsens beyond -$0.95 in FY26 or fails to improve toward -$0.51 in FY27 |
Diluted EPS: $-0.20 per share FY2026-Q2; GAAP. Published target: EPS loss <= -$0.51. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-0.2 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to at least $7.4M in FY27 | A primary condition in Dare Bioscience Inc's published investment case. The stated target is >= $7.4M total revenue. | Broken | revenue falls below $2.1M in FY26 or fails to grow toward $7.4M in FY27 | Revenue: $187,546 FY2026-Q2; GAAP. Published target: >= $7.4M total revenue. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026187,546 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.48 → $-0.51 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-25 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-26 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-27 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-28 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-29 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-30 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-07-31 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-01 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-02 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-03 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-04 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-05 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-06 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-07 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-08 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-09 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-10 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-11 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-12 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-13 | $-0.51 | $7,389,500 | 1 / 2 |
| 2026-08-14 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-15 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-16 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-17 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-18 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-19 | $-0.48 | $7,389,500 | 1 / 1 |
| 2026-08-20 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-21 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-22 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-23 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-24 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-25 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-26 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-27 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-28 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-29 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-30 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-08-31 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-01 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-02 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-03 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-04 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-05 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-06 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-07 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-08 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-09 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-10 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-11 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-12 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-13 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-14 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-15 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-16 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-17 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-18 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-19 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-20 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-21 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-22 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-23 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-24 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-25 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-26 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-27 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-28 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-29 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-09-30 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-01 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-02 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-03 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-04 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-05 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-06 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-07 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-08 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-09 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-10 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-11 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-12 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-13 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-14 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-15 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-16 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-17 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-18 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-19 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-20 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-21 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-22 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-23 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-24 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-25 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-26 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-27 | $-0.41 | $8,863,500 | 1 / 1 |
| 2026-10-28 | $-0.51 | $6,719,000 | 2 / 2 |
| 2026-10-29 | $-0.51 | $6,719,000 | 2 / 2 |
| 2026-10-30 | $-0.51 | $6,719,000 | 2 / 2 |
| 2026-10-31 | $-0.51 | $7,397,500 | 2 / 2 |
| 2026-11-01 | $-0.51 | $7,397,500 | 2 / 2 |
| 2026-11-02 | $-0.51 | $7,397,500 | 2 / 2 |
| 2026-11-03 | $-0.51 | $7,397,500 | 2 / 2 |
| 2026-11-04 | $-0.51 | $7,397,500 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.